
A NEW IDEA ON BIOTECH CYTK — GOOD TRIAL DATA — BUYOUT TARGET
By Nigam Arora & Dr. Natasha Arora CYTK is demonstrating good trial data in patients with obstructive hypertrophic cardiomyopathy. The data shows aficamten is superior to the current standard of care beta blockers. CYTK is a buyout target. To date, 205 Arora portfolio companies have been bought out. Producing a fortune for members who routinely invest in buyout targets. This record is better than firms that charge upwards of $50K per year. With The Arora Report, you get so much more. Zones For those following the Good Way, the Buy Now rating is *** (To see the locked content, please take a